Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature

Journal of Chemotherapy

Volumn 21, Issue 2, 2009, Pages 211-214

  Bassetti, M ^a   Repettox, E ^a   Mikulska, M ^a   Miglino, M ^a   Clavio, M ^a   Gobbi M , ^a   Righi, E ^a   Viscoli, C ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; Cryptococcosis; Liposomal amphothericin B

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AMIKACIN; AMPHOTERICIN B LIPID COMPLEX; CEFEPIME; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GEMCITABINE; IMMUNOGLOBULIN; MITOXANTRONE; PIPERACILLIN PLUS TAZOBACTAM; RITUXIMAB; THALIDOMIDE;

AGED; ANEMIA; ARTICLE; BLOOD EXAMINATION; CANCER PATIENT; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FUNGEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MAXILLA SINUSITIS; NEUTROPENIA; PLEURA EFFUSION; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 67249134161     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.2.211     Document Type: Article

References (21)

1. Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 2006;20(3):507-44, v-vi.
2. Diamond RD, Bennett JE. Prognostic factors in crypto-coccal meningitis. A study in 111 cases. Ann Intern Med 1974;80(2):176-81.
3. Perfect JR. Cryptococcus neoformans. In: Mandel GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Churchill Livingstone 2005: 2997-3012.
4. Whimbey E, Gold JW, Polsky B, Dryjanski J, Hawkins C, Blevins A, et al. Bacteremia and fungemia in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986;104(4):511-4.
5. Jean SS, Fang CT, Shau WY, Chen YC, Chang SC, Hsueh PR, et al. Cryptococcaemia: clinical features and prognostic factors. Qjm 2002;95(8):511-8.
6. Prendiville S, Bielamowicz SA, Hawrych A, Deeb ZE. Isolated cryptococcal sphenoid sinusitis with septicemia, meningitis, and subsequent skull base osteomyelitis in an immunocompetent patient. Otolaryngol Head Neck Surg 2000;123(3):277-9.
7. Ravandi F, O'Brien S. Alemtuzumab. Expert Rev Anti-cancer Ther 2005;5(l):39-51.
8. Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006;132(l):3-12.
9. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43(l): 16-24.
10. Nosari A, Tedeschi A, Ricci F, Montillo M. Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. Haematologica 2008;93(2):e30-l.
11. Molica S, Levato D, Levato L. Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up. Haematologica 1993;78(6):374-7.
12. Ravandi F, Anaissie EJ, O'Brien S. Infections in chronic leukemias and other haematological malignancies. In: Bowden JR, Wa RA, editor. Management of Infection in Oncology Patients. London: Martin Dunitz; 2003. p. 105-128.
13. Tarn CS, Wolf MM, Januszewicz EH, Grigg AP, Prince HM, Westerman D, et al. A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer 2004; 101 (9): 2042-9.
14. Laros-van Gorkom BA, Huisman CA, Wijermans PW, Schipperus MR. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. Neth J Med 2007;65(9):333-8.
15. Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007;44(2):204-12.
16. Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc 2005;37(2):934-6.
17. Silveira FP, Husain S, Kwak EJ, Linden PK, Marcos A, Shapiro R, et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transpl Infect Dis 2007;9(l):22-7.
18. Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S. Campath-IH induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006;81(l):17-20.
19. Walsh R, Ortiz J, Foster P, Palma-Vargas J, Rosenblatt S, Wright F. Fungal and mycobacterial infections after Campath (alemtuzumab) induction for renal transplantation. Transpl Infect Dis 2008;10(4):236-9.
20. Ortiz J, Palma-Vargas J, Wright F, Bingaman A, Agha I, Rosenblatt S, et al. Campath induction for kidney transplantation: report of 297 cases. Transplantation 2008;85(ll): 1550-6.
21. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007;78(4):275-82